As anticipation builds around the Union Budget 2025, investors, businesses, and policymakers eagerly await key reforms that could reshape the economic landscape. This year’s budget is expected to ...

Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million. Read why RPRX ...

Many investors seemed to view Nvidia's decision to maintain its stake in Recursion as a vote of confidence in the company.

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

We recently compiled a list of the 10 Under-the-Radar Stocks with Massive Upside for 2025. In this article, we are going to take a look at where BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ...

Royalty Pharma (RPRX) expects 2025 Portfolio Receipts to be between $2,900 million and $3,050 million, representing expected growth of 4% to ...

EST Recursion Pharmaceuticals (RXRX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Indian benchmark indices managed to settle with decent gains, following a volatile trading session, on the back of strength in the banking stocks ... Mankind Pharma, Adani Energy Solutions ...

West Pharmaceutical Services, Inc. WST is well poised for growth, backed by the robust Proprietary Products segment and sustained strength in research and development (R&D). However, foreign ...

The equity sector mutual fund schemes that bet primarily on the pharmaceutical and healthcare stocks have fared well over the last two years, following a disappointing performance in 2022.